The Chinese-German Journal of Clinical Oncology (Chin Ger J Clin Oncol )

Publisher: Chinese-German Society of Medicine; German-Chinese Society of Medicine, Springer Verlag

Description

The Chinese-German Journal of Clinical Oncology is an international professional academic periodical on oncology, being co-edited by China and Germany. The Journal, with the authors from around world, especially from China, is dominated in introducing the clinical experience of diagnosis and treatment as well as leading scientific research archievement in the tumor domain, in addition to report basic theory researches which help instruct the clinical practice of oncology and closely connect with the discipline. All the manuscripts are published in English, quarterly issued both internal and external, 64-80 pages, big 16 opens domains, art paper in offset printing, with lay.out by international customs, unified issuing number: ISSN 0178-3351/CN/42-1654/R.

Impact factor 0.00

  • 5-year impact
    0.00
  • Cited half-life
    0.00
  • Immediacy index
    0.00
  • Eigenfactor
    0.00
  • Article influence
    0.00
  • Website
    The Chinese-German Journal of Clinical Oncology website
  • Other titles
    Chinese-German journal of clinical oncology (Online)
  • ISSN
    1610-1979
  • OCLC
    55949344
  • Material type
    Document, Periodical, Internet resource
  • Document type
    Internet Resource, Computer File, Journal / Magazine / Newspaper

Publisher details

Springer Verlag

  • Pre-print
    • Author can archive a pre-print version
  • Post-print
    • Author can archive a post-print version
  • Conditions
    • Author's pre-print on pre-print servers such as arXiv.org
    • Author's post-print on author's personal website immediately
    • Author's post-print on any open access repository after 12 months after publication
    • Publisher's version/PDF cannot be used
    • Published source must be acknowledged
    • Must link to publisher version
    • Set phrase to accompany link to published version (see policy)
    • Articles in some journals can be made Open Access on payment of additional charge
  • Classification
    ​ green

Publications in this journal

  • [Show abstract] [Hide abstract]
    ABSTRACT: The laryngeal mask airway (LMA) is an established way for airway control during spontaneous ventilation. Its ability to deliver positive pressure ventilation without leakage especially in low flow states is still controversy. The aim of this study is to test the possibility of using LMA in pediatric closed circuit controlled ventilation, and to find out the optimum cuff volume to perform closed system ventilation.Twenty children scheduled for elective surgeries were enrolled in a crossover study. Laryngeal mask airway was used. In stage I, the cuff was inflated with the maximum volume of air as recommended by the manufacturers. Adjustment of volume of air inflated into the LMA cuff to the minimum volume to obtain the effective seal was done at stage II. The leak pressure, intracuff pressure and the leak volume were measured in both stages.The cuff filling volume was significantly lower compared to the maximum cuff inflation volume in stage I. Leakage values showed significantly less values in stage II of the study with smaller cuff inflation volumes. The airway leakage pressure was significantly lower in stage II in comparison to stage I. Cuff inflation pressure in stage I showed marked elevation which dropped significantly after adjustment of cuff volume in stage II.Laryngeal mask airway is an effective tool to provide closed circuit controlled ventilation in pediatrics. Inflation of the cuff by the minimum volume of air needed to reach the just sealing pressure is suggested to minimize the leakage volume.
    The Chinese-German Journal of Clinical Oncology 12/2013; 12(12).
  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this study was to study the short-term curative effects and adverse reactions of docetaxel (DOC) in concurrent chemoradiotherapy compared to DDP plus 5-Fu (DF) combined with concurrent radiotherapy in patients with advanced nasopharyngeal carcinoma.Thirty-three patients in the experimental group (DOC group) were given DOC 25 mg/m2 ivgtt, d1, 7 times, concurrent radiotherapy was performed from d1. Thirty-three patients in the control group (DF group) were given cisplatin 25 mg/m2 ivgtt d1-3 and 5-Fu 550 mg/m2 iv, d1-5, 3 weeks a cycle, 2 cycles, and concurrent radiotherapy was performed from d1. Six MV X-ray and 9 MeV electronic line for external irradiation were adopted in concurrent radiotherapy.The response rates of DOC group and DF group were 90.9% and 93.9%, the rates of neutropenia were 45.45% and 67.74%, and the rates of oral mucositis were 60.61% and 90.32%.The difference of short-term curative effects between DOC group and DF group was not statistically significant in patients with advanced nasopharyngeal carcinoma. The rates of adverse reactions were lower in DOC group. DOC combined with concurrent radiotherapy could be a new choice for patients with advanced nasopharyngeal carcinoma.
    The Chinese-German Journal of Clinical Oncology 12/2013; 12(12).
  • [Show abstract] [Hide abstract]
    ABSTRACT: A case with an Alpha-fetoprotein-producing (AFP-producing) carcinoma originating from the rectum was described. A 41-year-old man, who underwent a palliative surgery for rectal carcinoma, was diagnosed with occupying liver lesions and a remarkable AFP elevation (3484.61 ng/mL), and the AFP declined obviously 10 days after the palliative surgery. So we carried out a biopsy of the liver lesions. The histopathology was reported as low differentiation adenocarcinoma. The immunohistochemistry of the tumor cells via liver biopsy showed: Villin, CDX-2 was positive, Glypican-3 was partial positive, CK7, CK20, AFP, Hepatocyte were all negative. The initial histopathology was reported as an AFP-producing rectum adenocarcinoma with liver metastasis, which was a rare disease. So far, only 17 reports, none has been reported in China. Then, we summarize the characteristic of the disease: diagnosed with hepatic metastasis, raised serum AFP and a poor outcome, in addition to primary symptoms. This kind of disease is highly malignant.
    The Chinese-German Journal of Clinical Oncology 12/2013; 12(12).
  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim of the study was to evaluate the efficacy and tolerability of single-agent gemcitabine in the maintenance treatment of histologically confirmed metastatic breast cancer cases.The 45 patients carried efficacious chemotherapy were divided into maintenance therapy group (n = 23) and control group (n = 22) according to the different treatment methods. Patients in the maintenance therapy group received gemcitabine therapy until 6 cycles, disease progression or adverse effect intolerance. Within the control group, the patients were given best supportive care. Follow-up was made until disease progression, death or 2 years. The short-term clinical efficacy and adverse effects, progression-free survival (PFS) and median survival of recurrence (MSR) of these two groups were compared and analyzed.Compared with the control group, the experiment group had higher response rate (RR; 73.9% vs 31.8%; P P P > 0.05). Most of the treatment-related adverse events were mild, and the most common adverse event was hematologic toxicity. The 3 cases occurred grades 3–4 neutropenia and 3 cases occurred grades 3–4 thrombocytopenia. The 1 patient stopped treatment because of grade 3 allergic reaction, and 4 patients required dose reduction for grade 4 adverse events. Other adverse effects were grades 1–2, and all were recovered after symptomatic treatment. There was no significant side effect which threatened the life.In the extension maintenance treatment, gemcitabine can consolidate the therapeutic effect in advance and significantly prolong median PFS of metastatic breast cancer patients. In conclusion, gemcitabine monotherapy with a favorable safety profile is an effective maintenance treatment in metastatic breast cancer patients.
    The Chinese-German Journal of Clinical Oncology 12/2013; 12(12).
  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this study was to evaluate effect and mechanism of 125I radioactive particles interposed radiotherapy between organizations on lung cancer.Fourteen cases of patients diagnosed with non-small cell lung cancer (NSCLC), the use of the B-, CT-guided, according to preoperative imaging and treatment planning system (TPS) program for radioactive particles interposed 125I interstitial radiotherapy.All patients were successfully 125I interstitial radioactive particles interposed radiotherapy. Postoperative local complete tumor remission in 9 cases, partial remission in 5 cases, the efficiency of 100%. No case of serious complications. After 3 to 4 weeks of chemotherapy after 11 cases. 4 cases of lung cancer with bone metastases, pain completely disappeared after treatment. Up to now, five cases have died due to tumor progression, survival time of 12 to 16 months. Nine cases still under follow-up observation and treatment.125I radioactive particles interposed radiotherapy between organizations of lung cancer, simple operation, trauma, fewer complications, conformal high, high local tumor dose, efficacy, and is a supplement of modern radiotherapy techniques for the treatment of lung cancer provides a comprehensive line of the method of effective.
    The Chinese-German Journal of Clinical Oncology 12/2013; 12(12).
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective The efficacy of preoperative transarterial chemoembolization (TACE) for hepatectomy on hepatocelluar carcinoma (HCC) is still controversial. This study aims to evaluate the efficacy of preoperative TACE on resectable HCC. Methods Pubmed, SCI, Medline, EMBASE, Cochrane Datebase, CNKI were searched. The articles that focused on preoperative TACE for resectable HCC, published from 1990 to 2012, were collected by computerized search of literatures and manual search of bibliographies. The relevant clinical trials’ data were reviewed by meta-analysis using the random effects model or fixed effect model by heterogeneity. The outcomes were expressed as odds ratio (OR) with 95% confidence intervals (CIs). Results A total of 1347 patients were included in these 7 studies, the cases were divided into the preoperative TACE group and the non-preoperative TACE group, and there was no difference between the two groups in the 3-year disease-free survival rate, with an odds ratio of 1.14 (95% CI = 0.90–1.45, P = 0.27); the 5-year disease-free survival rate in the preoperative TACE group was better than that in the non-TACE group with an odds ratio of 1.35 (95% CI = 1.07–1.74, P = 0.02); the 5-year overall survival rate in the preoperative TACE group was higher than that in the non-TACE group with an odds ratio of 0.59 (95% CI = 0.46–0.77, P Conclusion The present data suggests that preoperative TACE has no different in improving the 3-year disease-free survival rate with non-TACE group for resectable HCC, while it can improve the 5-year disease-free survival rate and the 5-year overall survival rate. More randomized controlled trials using large sample size are needed to provide sufficient evidence to confirm current conclusion.
    The Chinese-German Journal of Clinical Oncology 11/2013; 12(11):532-536.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective The aim of this study was to measure the leakage by two methods with ion chamber and ready packs film, and to investigate the feasibility and the advantages of using two dosimetry methods for assessing leakage radiation around the head of the linear accelerators. Methods Measurements were performed using a 30 cm3 ion chamber; the gantry at 0°, the X-ray head at 0°, the field size at between the central axis and a plane surface at a FSD of 100 as a reference, a series of concentric circles having radii of 50, 75, and 100 cm with their common centre at the reference point. The absorbed dose was measured at the reference point, and this would be used as the reference dose. With the diaphragm closed, the measurements were taken along the circumference of the three circles and at 45° intervals. Results Leakage radiations while the treatment head was in the vertical position varied between 0.016%–0.04%. With the head lying horizontally, leakage radiation was the same order magnitude and varied between 0.02%–0.07%. In the second method, the verification was accomplished by closing the collimator jaws and covering the head of the treatment unit with the ready pack films. The films were marked to permit the determination of their positions on the machine after exposed and processed. With the diaphragm closed, and the ready packs films around the linear accelerator the beam turned on for 2500 cGy (2500 MU). The optical density of these films was measured and compared with this of the reference dose. Leakage radiation varied according to the film positions and the magnitude of leakage was between 0.005%–0.075%. Conclusion The differences between the values of the leakage radiation levels observed at different measurement points do not only reflect differences in the effective shielding thickness of the head wall, but are also related to differences in the distances between the target and the measurement points. The experimental errors involved in dosimetric measurement also contribute to such differences.
    The Chinese-German Journal of Clinical Oncology 09/2013; 12(9):435-438.
  • [Show abstract] [Hide abstract]
    ABSTRACT: MicroRNAs (miRNAs) are small endogenous non-coding RNAs which can specifically silence gene expression, and thereby alter cell and organism phenotype. Deregulation of miRNA expression has been discovered in a variety of tumors and it is now clear that they contribute to cancer development and progression. Previous studies have indicated that miRNAs are involved in developmental timing, cell proliferation, apoptosis, morphogenesis [1], antiviral defense [2], and tumorigenesis [3]. In cancer pathways, altered expression of tumor suppressive or oncogenic miRNAs can disrupt regulatory mechanisms normal. Altered miRNAs expression patterns have been observed in a variety of diseased tissues. Cervical cancer is the most common malignant tumor in female reproductive tract. Recently more and more study showed a large number of miRNAs were down-regulated or up-regulated in cervical cancer. Recent data revealed that miRNA-218 (miR-218) played important roles in tumor initiation and development. This review focuses on analysis of miR-218 and will provide some insight into the progress of cervical cancer.
    The Chinese-German Journal of Clinical Oncology 08/2013; 12(8):399-402.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective The aim of this study was to explore the relationship between p53 gene and triple-negative breast cancer (TNBC), and determine that whether p53 gene could be a new effective therapeutic target. Methods We identified studies with quantitative data on the relation of p53 gene and TNBC through searching 12 databases online (Oct. 1999–Oct. 2012) and reviewing the references, which were written in English or Chinese. Summary estimates of odds ratio (OR) was calculated using the fixed-effects model or the random-effects model as appropriate. Results We identified 12 eligible studies with 1532 cases of TNBC patients and 6329 controls of non-TNBC patients. The test for homogeneity resulted in χ2 = 200.16 (P TNBC group than that in non-TNBC group [OR = 2.10, 95% confidence interval (CI) = 1.21–3.65]. In ethnicity-subgroup analysis, we found that in Caucasian group, the expression of p53 gene were stronger in TNBC group (OR = 2.60, 95% CI = 1.21–5.57), but there was no statistical significance in Asian group (OR = 1.69, 95% CI = 0.83–3.45). Conclusion P53 gene could be an effective predictor and a good therapeutic target for TNBC patients in the future, especially in Caucasian. Further researches focusing on p53 gene would gain a breakthrough in the treatment of TNBC.
    The Chinese-German Journal of Clinical Oncology 08/2013; 12(8):369-373.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective Very low density lipoprotein receptor (VLDLR) has been considered as a multiple function receptor due to binding numerous ligands, causing endocytosis and regulating cellular signaling. Our group previously reported that type II VLDLR overexpression in breast cancer tissues. The purpose of this study is to characterize type II VLDLR activities during cell migration using breast cancer cell lines. Methods Western blotting was used to test protein expression. Cell migration was analyzed by Scratch wound assay. The mRNA expression was tested by realtime-PCR. Reporter assay was to test the transcription activity. Results Scratch wound and Report assay indicated up-regulated VLDLR II expression promotes cell migration via activating Wnt/β-catenin pathway. The target genes such as VEGF, MMP2 and MMP7 were upregulated in VLDLR II overexpressed cells. On the contrary, cells treated with TFPI had an inhibition effect of cell migration response to down-regulation of VLDLR II. Conclusion Type II VLDLR conferred a migration and invasion advantage by activating Wnt/β-catenin pathway, then up-regulating VEGF, MMP2 and MMP7 in breast cancer cells.
    The Chinese-German Journal of Clinical Oncology 08/2013; 12(8):374-378.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective The aim of the study was to explore the effect of demethylating agent 5-Aza-2′-deoxycytidine (5-ADC) on expression of Fanconi anemia complementation group F (FANCF) gene and the proliferation of cervical cancer cells, to observe cell’s sensitivity to chemotherapeutic drug taxol, and to explore the antitumor effect of 5-ADC as well as the new treatment of cervical cancer. Methods Cervical cancer cell lines SiHa (FANCF gene full-methylated) and Hela (unmethylated) were treated with 5-ADC. We used the methylation-specific PCR (MSP), reverse transcription-polymerase chain reaction (RT-PCR) and Western blot to detect the FANCF methylation, mRNA and protein respectively. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was used to detect the proliferation of cells. The cytotoxicity of taxol was measured by flow cytometer. The nude mice bearing SiHa was used to observe the effect of 5-ADC in vivo. Results Inhibition of DNA promoter methylation by 5-ADC reactivated the expression of FANCF mRNA and protein in SiHa cells, consistent with decreased growth speed and increased taxol resistance. These results were proven in experiments in vivo. Conclusion The 5-ADC probably become a potential treatment drug through inhibiting the proliferation of cervical cancer cells in taxol-resistant patients.
    The Chinese-German Journal of Clinical Oncology 07/2013; 12(7).
  • The Chinese-German Journal of Clinical Oncology 07/2013; 12(7).
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective The aim of our study was to evaluate the pathological features of posterior echo attenuation of papillary thyroid microcarcinoma (PTMC) and cystic degeneration of cervical lymph node metastasis. Methods We retrospectively evaluated the ultrasound results from 36 cases of PTMC with 20 nodules of cystic degeneration of cervical lymph node metastasis and correlated the results with the histopathologic findings. Results The preliminary study indicated certain correlation between histopathologic findings and ultrasound results of posterior echo attenuation of papillary thyroid microcarcinoma and cystic degeneration of cervical lymph node metastasis. Conclusion Posterior echo attenuation detected by ultrasound was associated with fibrous structures in PTMC nodules, while cystic degeneration and papillary changes of cervical lymph node metastasis in PTMC showed liquefactive necrosis, degenerative changes and enlarged follicular of nodular structures.
    The Chinese-German Journal of Clinical Oncology 07/2013; 12(7).
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective Metadherin (MTDH) could regulate epithelial-mesenchymal transition (EMT), and is involved in tumor metastasis. This study was designed to observe the effect of MTDH-short hairpin RNA (shRNA) on EMT, and the role of MTDH in breast tumor metastasis. Methods RNA interference plasmid that can express shRNA targeting MTDH or shRNA-negative plasmid that does not match any known human coding mRNA was designed, constructed and named MTDH-shRNA and MTDH-shRNA-neg, which were transiently transfected into MDA-MB-231 cells using Lipofectamine™2000. After 48 h, the levels of MTDH, E-cadherin and α-SMA expression were determined by reverse transcription-polymerase chain reactin (RTPCR), Western blot. The invasion and immigration potential was examined by Transwell chamber invasion or migration assay. Results Compared with MDA-MB-231, the MTDH mRNA level was down-regulated by 41.2%, the MTDH protein level was down-regulated by 40.3%. The invasion and immigration potential of MDA-MB-231 cells was decreased after transfection of MTDH-shRNA. Compared with MDA-MB-231 or MTDH-shRNA-neg, the mRNA and protein level of α-SMA was reduced and E-candherin were increased in MTDH-shRNA, with statistical significance. Conclusion Downregulation of MTDH increase E-candherin expression and reduced α-SMA expression, which inhibit EMT in MDA-MB-231 cells. This knockdown significantly suppresse migration and invasion in MDA-MB-231 cells.
    The Chinese-German Journal of Clinical Oncology 07/2013; 12(7).
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective The aim of this study was to use lung cancer targeting binding polypeptide ZS-9 to screen cDNA library of human lung cancer and obtain ZS-9 specific ligand to confirm tumor marker of non small-cell lung cancer. Methods Artificially synthesize biotin labeled peptide ZS-9, anchored ZS-9 in the enzyme label plate coupled by avidin, used ZS-9 as probe to screen cDNA library of human lung cancer, after screening, obtained bacteriophage clone specifically binding with anchored polypeptide ZS-9. Extracted plasmid of bacteriophage and performed sequencing after amplified by PCR. Results It was demonstrated by bioinformatic analysis on the sequence of ligand binded by lung cancer specific peptide ZS-9 that the ligand was the cytoskeletal protein periplakin on the surface of lung cancer cells, suggesting that periplakin might be a new marker for non-small-cell lung cancer in lung cancer. Conclusion Use specific lung cancer binding peptide to screen new tumor marker periplakin in lung cancer and further studies on its biologic functions in genesis and development of lung cancer are still needed.
    The Chinese-German Journal of Clinical Oncology 07/2013; 12(7).
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective The aim of this study was to establish the osteosarcoma cell sublines which stably expressing tumor suppressor in lung cancer-1 (TSLC1) gene and evaluate its effect on growth inhibition of human osteosarcoma cell line MG63. Methods The recombinant plasmid pCI-TSLC1 was stably transfected into MG63 cells with Lipofectamine 2000. The positive clones were developed by selection by G418. Biological characteristics of one of the 6 cell lines which highly expressing TSLC1, namely, the M8T were studied. Cell growth was analyzed with MTT assay. 2 × 107 cells suspended in 0.2 mL phosphate buffered saline (PBS) were injected into the two flanks of 5-6-week-old female BALB/C nu/nu athymic nude mice. The volumes of subcutaneous of tumor growth were evaluated and calculated by the formula V= Length × Width × Height × 0.5 once a week. Results The M8T cell subline which stably expressing TSLC1 was characterized by Western blot. The genetic stability and purity of M8T cells were stable. TSLC1 significantly suppressed the growth of M8T cells in vitro. Moreover, the tumorigenicity of M8T cells was suppressed in vivo. Conclusion The osteosarcoma cell sublines M8T which stably expressing TSLC1 had been successfully established. The ability of growth and metastasis of M8T was significantly suppressed both in vitro and in vivo.
    The Chinese-German Journal of Clinical Oncology 07/2013; 12(7).
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective The aim of this study was to study the expression and the clinical significance of B7-H1 on dendritic cells (DCs) in peripheral blood from patients with bladder cancer. Methods Peripheral blood mononuclear cell were disparted from 30 bladder cancer patients and 7 healthy controls by density gradient centrifugation and then co-cultured. The expression of B7-H1 on DCs were analyzed by flow cytometry. Results Expression of B7-H1 on DCs in bladder cancer was higher than healthy controls (P < 0.01). And the expression were strongly associated with the pathological grade and clinical stage of bladder cancer (P < 0.05). Conclusion The up-regulation of B7-H1 on DCs was strongly associated with neoplastic progression of bladder cancer. B7-H1/programmed death (PD)-1 signal pathway may also play an important role in immune escape of bladder cancer during initial phase of T cell immune response.
    The Chinese-German Journal of Clinical Oncology 06/2013; 12(6).
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective The aim of this study was to investigate whether astrocyte elevated gene 1 (AEG1) regulates COX-2 expression in human hepatoma HepG2 cells and related pathways involved in this process. Methods Human hepatoma HepG2 cells were transfected with pcDNA3.1(-)-AEG1 plasmid or psilencer2.0-AEG1-shRNA1 plasmid to up/down-regulate AEG1 expression, pcDNA3.1(-) and psilencer 2.0 empty vector plasmids were transfected respectively as control. Real-time RT-PCR was carried out to measure the expression levels of AEG1 and COX-2 mRNA. The expression levels of AEG1 and COX-2 protein were detected by Western blot. NF-κB signaling was blocked by PDTC, and AP-1 signaling was blocked by curcumin. Results AEG1 mRNA and protein levels were increased after pcDNA3.1(-)-AEG1 transfection, and decreased after psilencer2.0-AEG1-shRNAs transfection. COX-2 mRNA and protein levels were increased in AEG1-overexpressing cells and decreased in AEG1-knockdown cells. Phosphorylations of p65 and c-jun were up-regulated in AEG1-overexpressing cells. Both PDTC and curcumin reduced COX-2 expression in HepG2 cells with AEG1 overexpression. Conclusion AEG1-overexpressing and -knockdown HepG2 cells are established successfully. AEG1 could induce COX-2 expression though activating NF-κB and AP-1 in human hepatoma HepG2 cells.
    The Chinese-German Journal of Clinical Oncology 06/2013; 12(6).